
Pasithea Therapeutics Corp (NASDAQ:KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory disorders.
Why It Is Important: Alpha-5's lead therapeutic candidate can potentially improve clinical outcomes in patients with ALS. Post-mortem studies support that and reproducible significant improvement in behavior and survival in the SOD1 mice model.